The file's text, extracted by GovTribe without its formatting.
SP4702-11-R-0001
Table of Contents
Description
Pages
Solicitation/Contract Form
1 through 2
Schedule of Supplies/Services
3 through 22 Performance Work Statement (PWS)
23 through 38 Provisions and Contract Clauses
39 through 72 Submit offers no later than August 26, 2011 1:00 p.m. Local Time to the following address:
If mailed via USPS regular mail:
DLA Land and Maritime ATTN: PBSF (Bldg. 20 Room A242N) P.O. Box 3990 Columbus, Ohio 43218-3990 If mailed via Private couriers (i.e., UPS or Fedex):
DLA Land and Maritime ATTN: PBSF (Bldg. 20 Room A242N) 3990 E. Broad St.
Columbus, Ohio 43213-1152
Site Visit is scheduled for Wednesday, August 10, 2011 10:00 a.m. Please contact Dorinda Conner at Dorinda.Conner@dla.mil with the company name and personnel that will attend at least two days prior to site visit (FAR 52.237-1, Site Visit).
SPECIAL NOTICES:
1. SEE PERFORMANCE WORK STATEMENT PARAGRAPH 5.1, SEASONAL INFLUENZA VACCINATIONS. OFFERORS MUST BE PREPARED TO OFFER VACCINATIONS DURING OCTOBER AND SHALL STATE AFFIRMATIVELY THEY CAN MEET THIS REQUIREMENT IN THEIR OFFER.
2. SEE ADDENDUM TO FAR 52.212-1, PARAGRAPH (b) (10): Offerors shall provide three past performance references of current users of their services. THE FAILURE TO SUBMIT REFERENCES MAY EXCLUDE THE OFFEROR FROM FURTHER CONSIDERATION.
| CLIN |
| Supplies/Services |
| Quantity* |
Amount
BASE YEAR, YEAR 1
| 0001 |
| Occupational Health Physician Services (I/A/W PWS paragraph 3.1) |
| 12 months |
| 0002 |
| Additional Occupational Health Physician hours (I/A/W PWS paragraph 3.1) |
| 0 |
| 0003 |
| Occupational Health Nurse Services (I/A/W PWS paragraph 2.0) |
| 12 months |
| 0004 |
| Additional Occupational Health Nurse hours (I/A/W PWS paragraph 5.1) |
| 0 |
| 0005 |
| Physical examination (except injuries) (I/A/W PSW paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 350 |
| 0006 |
| Injury & illness examinations (I/A/W PWS paragraph 1.7) |
| 160 |
| 0007 |
| Audiograms (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 280 |
| 0008 |
| Masking Audiograms (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 4 |
| 0009 |
| Pulmonary Function (FVC, FEV1, FEV1/FVC) (I/A/W PWS paragraphs 3.2.2, 3.2.3. and 3.2.4) |
| 210 |
| 0010 |
| EKG (I/A/W PWS paragraphs 3.2.2, 3.2.3. and 3.2.4) |
| 140 |
| 0011 |
| Chest X-ray (2 views, “B” reader) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 15 |
| 0012 |
| Extremity(ies) X-ray (I/A/W PWS paragraph 1.7) |
| 20 |
| 0013 |
| Head/Spine X-ray (I/A/W PWS paragraph 1.7) |
| 5 |
| 0014 |
| Splints (I/A/W PWS paragraph 1.7) |
| 10 |
| 0015 |
| Blood Lead (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 30 |
| 0016 |
| Zinc Protoporphtrin (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 30 |
| 0017 |
| Complete Blood Count (including Platelet and Differential) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 0018 |
| Blood Chemistry (including but not limited to: glucose, BUN, SGOT, creatine, alkaline phosphates, total bilirubin, GGT, cholesterol) |
(I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4)
| 0019 |
| Cholinesterase (RBC and serum) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 8 |
| 0020 |
| Carboxyhemoglobin (I/A/W PWS paragraph 3.2.3) |
| 4 |
| 0021 |
| Human Immunodeficiency Virus (HIV) blood test (I/A/W PWS paragraph 3.2.4) |
| 120 |
| 0022 |
| PPD (Tuberculosis) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 170 |
| 0023 |
| Urinalysis w/microscopic examination (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 60 |
| 0024 |
| Urinalysis Dip (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 250 |
| 0025 |
| Vision Screening (I/A/W PWS paragraph 3.2.3.4) |
| 360 |
| 0026 |
| Cadmium (blood) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 0027 |
| Cadmium (Urine) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 0028 |
| Beta 2 Microglobulin (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 0029 |
| Creatinine (Urine(I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 0030 |
| Renal Panel (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 0031 |
| Pregnancy Test (Urine) (I/A/W PWS paragraph 3.2.4) |
| 0032 |
| Malaria Pills – Mefloquine 250 mg (4 tablets)(1 mo supply) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 36 |
| 0033 |
| Malaria Pills – Chloroquine 500 mg (4 tablets) (1 mo supply) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 30 |
| 0034 |
| Malaria Pills – Doxycyline 100 mg (30 capsules) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 30 |
| 0035 |
| Typhoid Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 36 |
| 0036 |
| Meningococcal Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 5 |
| 0037 |
| Japanese Encephalitis Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 2 |
| 0038 |
| Yellow Fever Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 2 |
| 0039 |
| Hepatitis A Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 200 |
| 0040 |
| Hepatitis A Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 5 |
| 0041 |
| Hepatitis B Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4, and 3.2.5) |
| 270 |
| 0042 |
| Hepatitis B Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 130 |
| 0043 |
| Hepatitis C Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 5 |
| 0044 |
| Varicella Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4, and 3.2.5) |
| 15 |
| 0045 |
| Varicella Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4 and 3.2.5) |
| 70 |
| 0046 |
| Rubella Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4 and 3.2.5) |
| 10 |
| 0047 |
| Mumps/Measles/Rubella (MMR) Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 70 |
| 0048 |
| Diptheria Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 36 |
| 0049 |
| Polio Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 90 |
| 0050 |
| Pre-rabies Vaccine (I/A/W PWS paragraph 3.2.3) |
| 2 |
| 0051 |
| Influenza Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 2600 |
| ** |
| ** |
Due to the volatile nature of the influenza vaccine, FOR EVALUATION PURPOSES ONLY, CLIN 0051, will be evaluated by multiplying the estimated quantity of 2600 ea, by the evaluation unit price of $15.00, plus an administrative fee per unit proposed by the offeror to arrive at a total amount for the CLIN.
To be completed by the offeror:
2600 each X ($15.00 ea plus an administration fee of $_________ per unit) = total amount of $___________________
**The contractor will be paid the quantity actually used for the CLIN by the unit price of the vaccine actually paid (verified upon submission of the vaccine invoice) plus the awarded administrative fee per unit. CLIN 0051 will be funded at the time services are required.
OFFERORS MUST BE PREPARED TO OFFER VACCINATIONS DURING OCTOBER AND SHALL STATE AFFIRMATIVELY THEY CAN MEET THIS REQUIREMENT IN THEIR OFFER.
| CLIN |
| Supplies/Services |
| Quantity* |
Amount
BASE YEAR, YEAR 1
| 0052 |
| Psychiatric Evaluations (I/A/W PWS paragraph 4.3) |
| 5 |
| 0053 |
| Health referrals (I/A/W PWS paragraph 4.3) |
| 10 |
| 0054 |
| Witness Services (I/A/W PWS paragraph 3.3) |
| 1hr |
| 0055 |
| CPR/AED Training (I/A/W PWS paragraphs 5.3) |
| 180 |
| 0056 |
| Fasting Lipids (I/A/W PWS paragraph 3.2.4) |
| 36 |
| 0057 |
| G6PD (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 18 |
| 0058 |
| Tetanus Diptheria Vaccine (TDAP) (I/A/W PWS paragraphs 1.7, 3.2.3, 3.2.4 and 3.2.5) |
| 110 |
| 0059 |
| HgbA1c (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 265 |
| 0060 |
| Health Screenings/Health Education (I/A/W PWS paragraph 5.2) |
| 6 |
*THE QUANTITIES LISTED ARE ESTIMATES ONLY FOR EVALUATION PURPOSES. THE CONTRACTOR WILL BE PAID ONLY FOR ACTUAL WORK PERFORMED. UNITS ARE “EACH” UNLESS OTHERWISE NOTED.
| CLIN |
| Supplies/Services |
| Quantity* |
Amount
OPTION 1, YEAR 2
| 1001 |
| Occupational Health Physician Services (I/A/W PWS paragraph 3.1) |
| 12 months |
| 1002 |
| Additional Occupational Health Physician hours (I/A/W PWS paragraph 3.1) |
| 0 |
| 1003 |
| Occupational Health Nurse Services (I/A/W PWS paragraph 2.0) |
| 12 months |
| 1004 |
| Additional Occupational Health Nurse hours (I/A/W PWS paragraph 5.1) |
| 0 |
| 1005 |
| Physical examination (except injuries) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 350 |
| 1006 |
| Injury & illness examinations (I/A/W PWS paragraph 1.7) |
| 160 |
| 1007 |
| Audiograms (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 280 |
| 1008 |
| Masking Audiograms (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 4 |
| 1009 |
| Pulmonary Function (FVC, FEV1, FEV1/FVC) (I/A/W PWS paragraphs 3.2.2, 3.2.3. and 3.2.4) |
| 210 |
| 1010 |
| EKG (I/A/W PWS paragraphs 3.2.2, 3.2.3. and 3.2.4) |
| 140 |
| 1011 |
| Chest X-ray (2 views, “B” reader) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 15 |
| 1012 |
| Extremity(ies) X-ray (I/A/W PWS paragraph 1.7) |
| 20 |
| 1013 |
| Head/Spine X-ray (I/A/W PWS paragraph 1.7) |
| 5 |
| 1014 |
| Splints (I/A/W PWS paragraph 1.7) |
| 10 |
| 1015 |
| Blood Lead (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 30 |
| 1016 |
| Zinc Protoporphtrin (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 30 |
| 1017 |
| Complete Blood Count (including Platelet and Differential) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 265 |
| 1018 |
| Blood Chemistry (including but not limited to: glucose, BUN, SGOT, creatine, alkaline phosphates, total bilirubin, GGT, cholesterol) |
| 1019 |
| Cholinesterase (RBC and serum) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 8 |
| CLIN |
| Supplies/Services |
| Quantity* |
Amount
OPTION 1, YEAR 2
| 1020 |
| Carboxyhemoglobin (I/A/W PWS paragraph 3.2.3) |
| 4 |
| 1021 |
| Human Immunodeficiency Virus (HIV) blood test (I/A/W PWS paragraph 3.2.4) |
| 120 |
| 1022 |
| PPD (Tuberculosis) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 170 |
| 1023 |
| Urinalysis w/microscopic examination (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 60 |
| 1024 |
| Urinalysis Dip (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 250 |
| 1025 |
| Vision Screening (I/A/W PWS paragraph 3.2.3.4) |
| 360 |
| 1026 |
| Cadmium (blood) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 1027 |
| Cadmium (Urine) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 1028 |
| Beta 2 Microglobulin (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 1029 |
| Creatinine (Urine(I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 1030 |
| Renal Panel (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 1031 |
| Pregnancy Test (Urine) (I/A/W PWS paragraph 3.2.4) |
| 10 |
| 1032 |
| Malaria Pills – Mefloquine 250 mg (4 tablets)(1 mo supply) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 36 |
| 1033 |
| Malaria Pills – Chloroquine 500 mg (4 tablets) (1 mo supply) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 30 |
| 1034 |
| Malaria Pills – Doxycyline 100 mg (30 capsules) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 30 |
| 1035 |
| Typhoid Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 36 |
| 1036 |
| Meningococcal Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 5 |
| 1037 |
| Japanese Encephalitis Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 2 |
| 1038 |
| Yellow Fever Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 1039 |
| Hepatitis A Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 200 |
| 1040 |
| Hepatitis A Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 5 |
| 1041 |
| Hepatitis B Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4, and 3.2.5) |
| 270 |
| 1042 |
| Hepatitis B Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 130 |
| 1043 |
| Hepatitis C Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 5 |
| 1044 |
| Varicella Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4, and 3.2.5) |
| 15 |
| 1045 |
| Varicella Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4 and 3.2.5) |
| 70 |
| 1046 |
| Rubella Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4 and 3.2.5) |
| 10 |
| 1047 |
| Mumps/Measles/Rubella (MMR) Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 70 |
| 1048 |
| Diptheria Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 36 |
| 1049 |
| Polio Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 90 |
| 1050 |
| Pre-rabies Vaccine (I/A/W PWS paragraph 3.2.3) |
| 2 |
| 1051 |
| Influenza Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 2600 |
| ** |
| ** |
Due to the volatile nature of the influenza vaccine, FOR EVALUATION PURPOSES ONLY, CLIN 1051, will be evaluated by multiplying the estimated quantity of 2600 ea, by the evaluation unit price of $15.00, plus an administrative fee per unit proposed by the offeror to arrive at a total amount for the CLIN.
To be completed by the offeror:
2600 each X ($15.00 ea plus an administration fee of $_________ per unit) = total amount of $___________________
**The contractor will be paid the quantity actually used for the CLIN by the unit price of the vaccine actually paid (verified upon submission of the vaccine invoice) plus the awarded administrative fee per unit. CLIN 1051 will be funded at the time services are required.
| CLIN |
| Supplies/Services |
| Quantity* |
Amount
OPTION 1, YEAR 2
| 1052 |
| Psychiatric Evaluations (I/A/W PWS paragraph 4.3) |
| 5 |
| 1053 |
| Health referrals (I/A/W PWS paragraph 4.3) |
| 10 |
| 1054 |
| Witness Services (I/A/W PWS paragraph 3.3) |
| 1hr |
| 1055 |
| CPR/AED Training (I/A/W PWS paragraphs 5.3) |
| 180 |
| 1056 |
| Fasting Lipids (I/A/W PWS paragraph 3.2.4) |
| 36 |
| 1057 |
| G6PD (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 18 |
| 1058 |
| Tetanus Diptheria Vaccine (TDAP) (I/A/W PWS paragraphs 1.7, 3.2.3, 3.2.4 and 3.2.5) |
| 110 |
| 1059 |
| HgbA1c (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 265 |
| 1060 |
| Health Screenings/Health Education (I/A/W PWS paragraph 5.2) |
| 6 |
*THE QUANTITIES LISTED ARE ESTIMATES ONLY FOR EVALUATION PURPOSES. THE CONTRACTOR WILL BE PAID ONLY FOR ACTUAL WORK PERFORMED. UNITS ARE “EACH” UNLESS OTHERWISE NOTED.
| CLIN |
| Supplies/Services |
| Quantity* |
Amount
OPTION 2, YEAR 3
| 2001 |
| Occupational Health Physician Services (I/A/W PWS paragraph 3.1) |
| 12 months |
| 2002 |
| Additional Occupational Health Physician hours (I/A/W PWS paragraph 3.1) |
| 0 |
| 2003 |
| Occupational Health Nurse Services (I/A/W PWS paragraph 2.0) |
| 12 months |
| 2004 |
| Additional Occupational Health Nurse hours (I/A/W PWS paragraph 5.1) |
| 0 |
| 2005 |
| Physical examination (except injuries) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 350 |
| 2006 |
| Injury & illness examinations (I/A/W PWS paragraph 1.7) |
| 160 |
| 2007 |
| Audiograms (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 280 |
| 2008 |
| Masking Audiograms (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 4 |
| 2009 |
| Pulmonary Function (FVC, FEV1, FEV1/FVC) (I/A/W PWS paragraphs 3.2.2, 3.2.3. and 3.2.4) |
| 210 |
| 2010 |
| EKG (I/A/W PWS paragraphs 3.2.2, 3.2.3. and 3.2.4) |
| 140 |
| 2011 |
| Chest X-ray (2 views, “B” reader) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 15 |
| 2012 |
| Extremity(ies) X-ray (I/A/W PWS paragraph 1.7) |
| 20 |
| 2013 |
| Head/Spine X-ray (I/A/W PWS paragraph 1.7) |
| 5 |
| 2014 |
| Splints (I/A/W PWS paragraph 1.7) |
| 10 |
| 2015 |
| Blood Lead (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 30 |
| 2016 |
| Zinc Protoporphtrin (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 30 |
| 2017 |
| Complete Blood Count (including Platelet and Differential) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 265 |
| 2018 |
| Blood Chemistry (including but not limited to: glucose, BUN, SGOT, creatine, alkaline phosphates, total bilirubin, GGT, cholesterol) |
| 2019AB |
| Cholinesterase (RBC and serum) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2020 |
| Carboxyhemoglobin (I/A/W PWS paragraph 3.2.3) |
| 4 |
| 2021 |
| Human Immunodeficiency Virus (HIV) blood test (I/A/W PWS paragraph 3.2.4) |
| 120 |
| 2022 |
| PPD (Tuberculosis) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 170 |
| 2023 |
| Urinalysis w/microscopic examination (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 60 |
| 2024 |
| Urinalysis Dip (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 250 |
| 2025 |
| Vision Screening (I/A/W PWS paragraph 3.2.3.4) |
| 360 |
| 2026 |
| Cadmium (blood) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 2027 |
| Cadmium (Urine) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 2028 |
| Beta 2 Microglobulin (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 2029 |
| Creatinine (Urine(I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 2030 |
| Renal Panel (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 2031 |
| Pregnancy Test (Urine) (I/A/W PWS paragraph 3.2.4) |
| 10 |
| 2032 |
| Malaria Pills – Mefloquine 250 mg (4 tablets)(1 mo supply) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 36 |
| 2033 |
| Malaria Pills – Chloroquine 500 mg (4 tablets) (1 mo supply) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 30 |
| 2034 |
| Malaria Pills – Doxycyline 100 mg (30 capsules) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 30 |
| 2035 |
| Typhoid Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 36 |
| 2036 |
| Meningococcal Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 5 |
| 2037 |
| Japanese Encephalitis Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 2 |
| 2038 |
| Yellow Fever Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 2039 |
| Hepatitis A Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 200 |
| 2040 |
| Hepatitis A Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 5 |
| 2041 |
| Hepatitis B Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4, and 3.2.5) |
| 270 |
| 2042 |
| Hepatitis B Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 130 |
| 2043 |
| Hepatitis C Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 5 |
| 2044 |
| Varicella Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4, and 3.2.5) |
| 15 |
| 2045 |
| Varicella Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4 and 3.2.5) |
| 70 |
| 2046 |
| Rubella Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4 and 3.2.5) |
| 10 |
| 2047 |
| Mumps/Measles/Rubella (MMR) Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 70 |
| 2048 |
| Diptheria Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 36 |
| 2049 |
| Polio Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 90 |
| 2050 |
| Pre-rabies Vaccine (I/A/W PWS paragraph 3.2.3) |
| 2 |
| 2051 |
| Influenza Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 2600 |
| ** |
| ** |
Due to the volatile nature of the influenza vaccine, FOR EVALUATION PURPOSES ONLY, CLIN 2051, will be evaluated by multiplying the estimated quantity of 2600 ea, by the evaluation unit price of $15.00, plus an administrative fee per unit proposed by the offeror to arrive at a total amount for the CLIN.
To be completed by the offeror:
2600 each X ($15.00 ea plus an administration fee of $_________ per unit) = total amount of $___________________
**The contractor will be paid the quantity actually used for the CLIN by the unit price of the vaccine actually paid (verified upon submission of the vaccine invoice) plus the awarded administrative fee per unit. CLIN 2051 will be funded at the time services are required.
| CLIN |
| Supplies/Services |
| Quantity* |
Amount
OPTION 2, YEAR 3
| 2052 |
| Psychiatric Evaluations (I/A/W PWS paragraph 4.3) |
| 5 |
| 2053 |
| Health referrals (I/A/W PWS paragraph 4.3) |
| 10 |
| 2054 |
| Witness Services (I/A/W PWS paragraph 3.3) |
| 1hr |
| 2055 |
| CPR/AED Training (I/A/W PWS paragraphs 5.3) |
| 180 |
| 2056 |
| Fasting Lipids (I/A/W PWS paragraph 3.2.4) |
| 36 |
| 2057 |
| G6PD (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 18 |
| 2058 |
| Tetanus Diptheria Vaccine (TDAP) (I/A/W PWS paragraphs 1.7, 3.2.3, 3.2.4 and 3.2.5) |
| 110 |
| 2059 |
| HgbA1c (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 265 |
| 2060 |
| Health Screenings/Health Education (I/A/W PWS paragraph 5.2) |
| 6 |
*THE QUANTITIES LISTED ARE ESTIMATES ONLY FOR EVALUATION PURPOSES. THE CONTRACTOR WILL BE PAID ONLY FOR ACTUAL WORK PERFORMED. UNITS ARE “EACH” UNLESS OTHERWISE NOTED.
| CLIN |
| Supplies/Services |
| Quantity* |
Amount
OPTION 3, YEAR 4
| 3001 |
| Occupational Health Physician Services (I/A/W PWS paragraph 3.1) |
| 12 months |
| 3002 |
| Additional Occupational Health Physician hours (I/A/W PWS paragraph 3.1) |
| 0 |
| 3003 |
| Occupational Health Nurse Services (I/A/W PWS paragraph 2.0) |
| 12 months |
| 3004 |
| Additional Occupational Health Nurse hours (I/A/W PWS paragraph 5.1) |
| 0 |
| 3005 |
| Physical examination (except injuries) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 350 |
| 3006 |
| Injury & illness examinations (I/A/W PWS paragraph 1.7) |
| 160 |
| 3007 |
| Audiograms (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 280 |
| 3008 |
| Masking Audiograms (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 4 |
| 3009 |
| Pulmonary Function (FVC, FEV1, FEV1/FVC) (I/A/W PWS paragraphs 3.2.2, 3.2.3. and 3.2.4) |
| 210 |
| 3010 |
| EKG (I/A/W PWS paragraphs 3.2.2, 3.2.3. and 3.2.4) |
| 140 |
| 3011 |
| Chest X-ray (2 views, “B” reader) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 15 |
| 3012 |
| Extremity(ies) X-ray (I/A/W PWS paragraph 1.7) |
| 20 |
| 3013 |
| Head/Spine X-ray (I/A/W PWS paragraph 1.7) |
| 5 |
| 3014 |
| Splints (I/A/W PWS paragraph 1.7) |
| 10 |
| 3015 |
| Blood Lead (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 30 |
| 3016 |
| Zinc Protoporphtrin (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 30 |
| 3017 |
| Complete Blood Count (including Platelet and Differential) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 265 |
| 3018 |
| Blood Chemistry (including but not limited to: glucose, BUN, SGOT, creatine, alkaline phosphates, total bilirubin, GGT, cholesterol) |
| 3019 |
| Cholinesterase (RBC and serum) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 3020 |
| Carboxyhemoglobin (I/A/W PWS paragraph 3.2.3) |
| 4 |
| 3021 |
| Human Immunodeficiency Virus (HIV) blood test (I/A/W PWS paragraph 3.2.4) |
| 120 |
| 3022 |
| PPD (Tuberculosis) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 170 |
| 3023 |
| Urinalysis w/microscopic examination (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 60 |
| 3024 |
| Urinalysis Dip (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 250 |
| 3025 |
| Vision Screening (I/A/W PWS paragraph 3.2.3.4) |
| 360 |
| 3026 |
| Cadmium (blood) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 3027 |
| Cadmium (Urine) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 3028 |
| Beta 2 Microglobulin (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 3029 |
| Creatinine (Urine(I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 3030 |
| Renal Panel (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 3031 |
| Pregnancy Test (Urine) (I/A/W PWS paragraph 3.2.4) |
| 10 |
| 3032 |
| Malaria Pills – Mefloquine 250 mg (4 tablets)(1 mo supply) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 36 |
| 3033 |
| Malaria Pills – Chloroquine 500 mg (4 tablets) (1 mo supply) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 30 |
| 3034 |
| Malaria Pills – Doxycyline 100 mg (30 capsules) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 30 |
| 3035 |
| Typhoid Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 36 |
| 3036 |
| Meningococcal Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 5 |
| 3037 |
| Japanese Encephalitis Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 2 |
| 3038 |
| Yellow Fever Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 3039 |
| Hepatitis A Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 200 |
| 3040 |
| Hepatitis A Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 5 |
| 3041 |
| Hepatitis B Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4, and 3.2.5) |
| 270 |
| 3042 |
| Hepatitis B Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 130 |
| 3043 |
| Hepatitis C Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 5 |
| 3044 |
| Varicella Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4, and 3.2.5) |
| 15 |
| 3045 |
| Varicella Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4 and 3.2.5) |
| 70 |
| 3046 |
| Rubella Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4 and 3.2.5) |
| 10 |
| 3047 |
| Mumps/Measles/Rubella (MMR) Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 70 |
| 3048 |
| Diptheria Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 36 |
| 3049 |
| Polio Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 90 |
| 3050 |
| Pre-rabies Vaccine (I/A/W PWS paragraph 3.2.3) |
| 2 |
| 3051 |
| Influenza Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 2600 |
| ** |
| ** |
Due to the volatile nature of the influenza vaccine, FOR EVALUATION PURPOSES ONLY, CLIN 3051, will be evaluated by multiplying the estimated quantity of 2600 ea, by the evaluation unit price of $15.00, plus an administrative fee per unit proposed by the offeror to arrive at a total amount for the CLIN.
To be completed by the offeror:
2600 each X ($15.00 ea plus an administration fee of $_________ per unit) = total amount of $___________________
**The contractor will be paid the quantity actually used for the CLIN by the unit price of the vaccine actually paid (verified upon submission of the vaccine invoice) plus the awarded administrative fee per unit. CLIN 3051 will be funded at the time services are required.
| CLIN |
| Supplies/Services |
| Quantity* |
Amount
OPTION 3, YEAR 4
| 3052 |
| Psychiatric Evaluations (I/A/W PWS paragraph 4.3) |
| 5 |
| 3053 |
| Health referrals (I/A/W PWS paragraph 4.3) |
| 10 |
| 3054 |
| Witness Services (I/A/W PWS paragraph 3.3) |
| 1hr |
| 3055 |
| CPR/AED Training (I/A/W PWS paragraphs 5.3) |
| 180 |
| 3056 |
| Fasting Lipids (I/A/W PWS paragraph 3.2.4) |
| 36 |
| 3057 |
| G6PD (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 18 |
| 3058 |
| Tetanus Diptheria Vaccine (TDAP) (I/A/W PWS paragraphs 1.7, 3.2.3, 3.2.4 and 3.2.5) |
| 110 |
| 3059 |
| HgbA1c (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 265 |
| 3060 |
| Health Screenings/Health Education (I/A/W PWS paragraph 5.2) |
| 6 |
*THE QUANTITIES LISTED ARE ESTIMATES ONLY FOR EVALUATION PURPOSES. THE CONTRACTOR WILL BE PAID ONLY FOR ACTUAL WORK PERFORMED. UNITS ARE “EACH” UNLESS OTHERWISE NOTED.
| CLIN |
| Supplies/Services |
| Quantity* |
Amount
OPTION 4, YEAR 5
| 4001 |
| Occupational Health Physician Services (I/A/W PWS paragraph 3.1) |
| 12 months |
| 4002 |
| Additional Occupational Health Physician hours (I/A/W PWS paragraph 3.1) |
| 0 |
| 4003 |
| Occupational Health Nurse Services (I/A/W PWS paragraph 2.0) |
| 12 months |
| 4004 |
| Additional Occupational Health Nurse hours (I/A/W PWS paragraph 5.1) |
| 0 |
| 4005 |
| Physical examination (except injuries) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 350 |
| 4006 |
| Injury & illness examinations (I/A/W PWS paragraph 1.7) |
| 160 |
| 4007 |
| Audiograms (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 280 |
| 4008 |
| Masking Audiograms (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 4 |
| 4009 |
| Pulmonary Function (FVC, FEV1, FEV1/FVC) (I/A/W PWS paragraphs 3.2.2, 3.2.3. and 3.2.4) |
| 210 |
| 4010 |
| EKG (I/A/W PWS paragraphs 3.2.2, 3.2.3. and 3.2.4) |
| 140 |
| 4011 |
| Chest X-ray (2 views, “B” reader) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 15 |
| 4012 |
| Extremity(ies) X-ray (I/A/W PWS paragraph 1.7) |
| 20 |
| 4013 |
| Head/Spine X-ray (I/A/W PWS paragraph 1.7) |
| 5 |
| 4014 |
| Splints (I/A/W PWS paragraph 1.7) |
| 10 |
| 4015 |
| Blood Lead (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 30 |
| 4016 |
| Zinc Protoporphtrin (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 30 |
| 4017 |
| Complete Blood Count (including Platelet and Differential) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 265 |
| 4018 |
| Blood Chemistry (including but not limited to: glucose, BUN, SGOT, creatine, alkaline phosphates, total bilirubin, GGT, cholesterol) |
| 4019 |
| Cholinesterase (RBC and serum) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 4020 |
| Carboxyhemoglobin (I/A/W PWS paragraph 3.2.3) |
| 4 |
| 4021 |
| Human Immunodeficiency Virus (HIV) blood test (I/A/W PWS paragraph 3.2.4) |
| 120 |
| 4022 |
| PPD (Tuberculosis) (I/A/W PWS paragraphs 3.2.2, 3.2.3, and 3.2.4) |
| 170 |
| 4023 |
| Urinalysis w/microscopic examination (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 60 |
| 4024 |
| Urinalysis Dip (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 250 |
| 4025 |
| Vision Screening (I/A/W PWS paragraph 3.2.3.4) |
| 360 |
| 4026 |
| Cadmium (blood) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 4027 |
| Cadmium (Urine) (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 4028 |
| Beta 2 Microglobulin (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 4029 |
| Creatinine (Urine(I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 4030 |
| Renal Panel (I/A/W PWS paragraphs 3.2.2 and 3.2.3) |
| 2 |
| 4031 |
| Pregnancy Test (Urine) (I/A/W PWS paragraph 3.2.4) |
| 10 |
| 4032 |
| Malaria Pills – Mefloquine 250 mg (4 tablets)(1 mo supply) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 36 |
| 4033 |
| Malaria Pills – Chloroquine 500 mg (4 tablets) (1 mo supply) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 30 |
| 4034 |
| Malaria Pills – Doxycyline 100 mg (30 capsules) (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 30 |
| 4035 |
| Typhoid Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 36 |
| 4036 |
| Meningococcal Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 5 |
| 4037 |
| Japanese Encephalitis Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 2 |
| 4038 |
| Yellow Fever Vaccine (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 4039 |
| Hepatitis A Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 200 |
| 4040 |
| Hepatitis A Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 5 |
| 4041 |
| Hepatitis B Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4, and 3.2.5) |
| 270 |
| 4042 |
| Hepatitis B Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 130 |
| 4043 |
| Hepatitis C Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4, and 3.2.5) |
| 5 |
| 4044 |
| Varicella Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4, and 3.2.5) |
| 15 |
| 4045 |
| Varicella Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4 and 3.2.5) |
| 70 |
| 4046 |
| Rubella Titer (I/A/W PWS paragraphs 3.2.2, 3.2.3, 3.2.4 and 3.2.5) |
| 10 |
| 4047 |
| Mumps/Measles/Rubella (MMR) Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 70 |
| 4048 |
| Diptheria Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 36 |
| 4049 |
| Polio Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 90 |
| 4050 |
| Pre-rabies Vaccine (I/A/W PWS paragraph 3.2.3) |
| 2 |
| 4051 |
| Influenza Vaccine (I/A/W PWS paragraphs 3.2.3, 3.2.4 and 3.2.5) |
| 2600 |
| ** |
| ** |
Due to the volatile nature of the influenza vaccine, FOR EVALUATION PURPOSES ONLY, CLIN 4051, will be evaluated by multiplying the estimated quantity of 2600 ea, by the evaluation unit price of $15.00, plus an administrative fee per unit proposed by the offeror to arrive at a total amount for the CLIN.
To be completed by the offeror:
2600 each X ($15.00 ea plus an administration fee of $_________ per unit) = total amount of $___________________
**The contractor will be paid the quantity actually used for the CLIN by the unit price of the vaccine actually paid (verified upon submission of the vaccine invoice) plus the awarded administrative fee per unit. CLIN 4051 will be funded at the time services are required.
| CLIN |
| Supplies/Services |
| Quantity* |
Amount
OPTION 4, YEAR 5
| 4052 |
| Psychiatric Evaluations (I/A/W PWS paragraph 4.3) |
| 5 |
| 4053 |
| Health referrals (I/A/W PWS paragraph 4.3) |
| 10 |
| 4054 |
| Witness Services (I/A/W PWS paragraph 3.3) |
| 1hr |
| 4055 |
| CPR/AED Training (I/A/W PWS paragraphs 5.3) |
| 180 |
| 4056 |
| Fasting Lipids (I/A/W PWS paragraph 3.2.4) |
| 36 |
| 4057 |
| G6PD (I/A/W PWS paragraphs 3.2.4 and 3.2.5) |
| 18 |
| 4058 |
| Tetanus Diptheria Vaccine (TDAP) (I/A/W PWS paragraphs 1.7, 3.2.3, 3.2.4 and 3.2.5) |
| 110 |
| 4059 |
| HgbA1c (I/A/W PWS paragraphs 3.2.2, 3.2.3 and 3.2.4) |
| 265 |
| 4060 |
| Health Screenings/Health Education (I/A/W PWS paragraph 5.2) |
| 6 |
*THE QUANTITIES LISTED ARE ESTIMATES ONLY FOR EVALUATION PURPOSES. THE CONTRACTOR WILL BE PAID ONLY FOR ACTUAL WORK PERFORMED. UNITS ARE “EACH” UNLESS OTHERWISE NOTED.
1.0. GENERAL.
1.1. SCOPE. The Defense Supply Center, Columbus (DSCC) is a 500-acre Federal site located at 3990 East Broad Street, Columbus, Ohio 43218-3990. DSCC requires occupational health services for approximately 6,500 individuals, not all individuals located on DSCC are covered under this contract. The Contracting Officer Technical Representative (COTR) will provide a list of organizations covered under this performance work statement (PWS) within ten days after award. The Contractor will not be reimbursed for services provided outside the organizations covered. Of the 6,500 individuals supported by this contract, approximately 200 are in an occupational medical surveillance program which is described in paragraph 3.2.5. The vast majority of services are expected to be delivered on site. Occupational medical services, other than those provided at the Nurses’ Stations, will be performed at a medical facility within a ten (10) mile radius of DSCC.
1.2. STAFF QUALIFICATIONS. All medical staff servicing this contract (including but not limited to clinics, laboratories, technicians, medical facility staff, and practitioners) shall possess qualifications derived from an accredited learning institution and be appropriately licensed in the State of Ohio. All staff who will be physically located at DSCC must be able to meet all security requirements as listed in Attachment 1. The Occupational Health Nurses (OHNs) must be registered nurses (RNs) have at least two years of full time occupational health nursing experience (i.e. nursing work responsibilities that required knowledge of the medical requirements in Occupational Safety and Health Administration (OSHA) and familiarity with and counseling individuals in health topics related to work place hazards.) Each OHN will receive at least (8) hours of continuing education annually and be licensed in the State of Ohio. The Occupational Health Physician (OHP) shall have a Doctor of Medicine (MD) degree or Doctor of Osteopathy Degree (DO) and be licensed in the State of Ohio. The OHP shall be certified by the American Board of Preventive Medicine in Occupational Medicine.
Deliverables: Copy of OHP’s medical license, occupational medicine certification, and proof of RNs’ licenses must be provided within 10 days of contract award.
1.3. MATERIALS AND SERVICES. The Contractor shall provide all materials and services necessary for performance of this contract, unless otherwise stated. All equipment for medical tests and procedures will meet current relevant American National Standards Institute (ANSI) Standards. The Government will provide space for Nurses’ Stations at DSCC. The stations will have utility, telephone and internet. Fax machines, photocopiers supplied with paper and computers with Microsoft Office (including encrypted email) will also be provided. The Government will provide only the following janitorial services for the Nurses’ Stations: removal of non-biohazardous trash, routine floor cleaning, and routine dusting of office areas. Government Property will be used only for the performance of this contract. Attachment 2: List of Government Equipment at Nurse’s Stations
1.4. STANDING OPERATING PROCEDURES (SOPs). SOPs for the Center will be authored and signed by the OHP and submitted to the Contract Officer Technical Representative (COTR) within 30 days of contract award, and within 10 days of any change to them. Compliance with the SOPs will be the responsibility of the OHP. The Contractor shall maintain a copy of the SOPs at the Contractor’s medical care facility (Clinic) and at each Nurse Station. The SOPs will be available for inspection by representatives of the Government.
Deliverables: Standing Operating Procedures.
1.5. CONTINUITY OF OPERATIONS PLAN. In the event of an emergency or threat at DSCC, the Contractor may not have access to one or both Nurses’ Stations. The COTR will inform the Contractor if this would be the case. During a continuity of operations event, all elements within this contract would need to be performed at the Clinic, except manning impacted Nurses’ Stations.
1.6. SEVERE WEATHER EMERGENCIES. DSCC will normally remain open and operational during severe weather conditions. On rare occasions, DSCC may be subject to a weather delay or closure. Delay and closure information will be announced on the radio and TV stations designated in Attachment 3. The Contractor may also call the number for Center-wide information at 614-692-1800 or TDD 614-692-1900. If a weather delay is announced, both nurse stations will operate on a revised schedule of 0730 to 1600. Nurses’ stations would be open from 0830 to 1600 if there was a one-hour delay.
1.7. COMMUNICABLE DISEASE PREVENTION.
1.7.1. The Contractor will be responsible to ensure that all procedures at the Clinic and the Nurses’ Stations comply with the Occupational Safety and Health Administration (OSHA) standards on communicable diseases.
1.7.2. Bloodborne Pathogens Exposure Control Plan. The Contractor will submit a Bloodborne Pathogens Exposure Control Plan to the COTR for approval no later than 30 days after contract award. The plan will include procedures for medical evaluation of individuals who are potentially exposed to bloodborne pathogens. The plan will specify that medical evaluations will commence no later than twenty-four hours after potential exposure, and it will require the Contractor to write a description of the circumstances surrounding the exposure. The Contractor will provide a written report that includes a treatment plan (if appropriate) within 48 hours to the COTR(Attachment 4). Copies of the Bloodborne Pathogens Control Plan shall be maintained at the Clinic and each Nurse Station, and they shall be available to representative of the Government.
Deliverable: Bloodborne Pathogens Exposure Control Plan.
1.8. REFUSAL OF MEDICAL SERVICES. If an individual refuses to submit to any required medical service, the Contractor will document the refusal in the individual’s medical record (Attachment 5) at the time of the refusal and notify the COTR within eight (8) working hours.
1.9. EXAMINATIONS AFTER INJURIES AND ILLNESSES. Individuals are required to report any on-the-job injury or illness that may be work related. A supervisor may send an individual or an individual may report directly to the Nurse Station after an injury occurs. An injury packet (Attachment 6-11) shall be provided to the individual. The injury packet includes both safety reporting and injury compensation forms. If the nurse determined the individual requires medical care beyond what can be provided at the Nurse Station and it is not life-threatening; the Nurse in conjunction with the DLA Installation Support Columbus, Environmental, Safety and Occupational Health Office (ESOH) will determine whether or not the case appears to be work related and provide recommendations on receiving additional medical care. The OHN will request approval of the COTR prior to sending an individual to the Clinic when further diagnosis/treatment is necessary. (Attachment 12). Deliverable: The Contractor will provide written documentation of services provided to the COTR within five (5) working days of the examination. (Attachment 13). Deliverable: The OHP will provide a written assessment, prognosis, and treatment provided when the individual is sent to the Clinic within 24 hours to the COTR. The following services are typically associated with injury/illness evaluations:
| CLIN(s) |
| Supplies/Services |
| 0006 |
| Injury & illness examinations |
| 0012 |
| Extremity(ies) X-ray |
| 0058 |
| Tetanus Diptheria Vaccine (TDAP) |
Services provided which do not exceed the contract agreement should be charged under the provisions of the contract. Should this patient need service/treatment beyond that covered in the contract, and for compensable injuries:
1.9.1 Advise the patient that further treatment is needed and will be provided as compensation reimbursable service. The patient has the right to seek a different provider for these services.
1.9.2 If Contractor is providing services beyond the contract, complete the Authorization for Examination And/Or Treatment Form CA-16 (Attachment 14) and the Medical Officer’s Report of Injury, DSCC Form 1157(Attachment 9). When a CA-16 is used, a CA-20 should NOT be completed. Fax to (614) 693-1569 the completed CA-16 Referral instructions form (Attachment 12), the completed CA-16, the completed DSCC 1157, and the list of contract services (Attachment 13) which were provided. Send the originals, and applicable billing (for services needed beyond those covered by the contract) to the Environmental, Safety & Health Office, DIS-CE, P.O. Box 3990; Columbus, OH 43218-3990; phone (614) 692-3964. The documents will be forwarded to the appropriate parties for processing.
OR
1.9.3 If referring the patient to another medical provider, including physical therapy, complete the CA-16 Referral instruction form and fax it to (614) 693-1569, along with the completed DSCC 1157 and a list of contract services which were provided. Patient should take the CA-16 to the referred medical provider.
1.10. TRANSPORTATION. The Contractor will not transport individuals for medical care. If emergency transportation is required, the Contractor will call Emergency Services dispatch at extension 2-2111. If an individual is unable to transport themselves during a non-emergency, the individual’s supervisor will be contacted to provide transportation.
1.11. MEETINGS. The OHP will attend meetings at DSCC at the request of the COTR no more often than once per week to discuss: medical services provided, the Contractor’s performance, and to provide medical opinions to the Government. One or both OHNs will attend at the specific request of the COTR. The OHP must be accessible within 4 hours to consult with Center management on occupational health matters. The OHP must be accessible within 4 hours to consult with Center management on public health emergencies to include epidemics, mass causality events, and acts of terrorism.
Deliverable: The Contractor will be responsible for keeping minutes of the meetings and providing a copy of them to the COTR within five (5) working days of the meetings.
1.12. OSHA COMPLIANCE. DSCC is a Voluntary Protection Program (VPP) Star Site. At a minimum, all services provided under this contract will comply with applicable OSHA standards. All interpretations of standards involving OSHA compliance will rest with ESOH. Representatives of the Government will have the right to inspect the Clinic and the Nurses’ Stations for compliance with Local, State, and Federal regulations during normal business hours.
1.13. OSHA RATES. As a VPP Star Site, we do review injury/illness rates for work performed at Defense Supply Center, Columbus.
Deliverable: OSHA Form 300A must be submitted by January 15th of each year for the previous calendar year. Hours worked and injury information should be reflective of activity which occurred at the Defense Supply Center, Columbus.
1.14. MISSED MEDICAL APPOINTMENTS. If an individual misses any scheduled medical appointment, the Contractor will document the time and date of the missed appointment in the individual’s medical record and contact the COTR within one (1) workday.
1.15. QUALITY CONTROL AND QUALITY ASSURANCE: The contractor shall submit a quality control plan in sufficient detail to ensure all work performed is completed in accordance with the contract requirements. The contractor shall submit the quality control plan for approval within 15 days of contract award. In accordance with the Government’s quality assurance surveillance plan, performance will be monitored through the required deliverables. The contactor shall designate an individual who will be responsible for all project quality control. Upon request by the Government, this individual shall meet as necessary to discuss quality control issues and concerns.
Deliverable: The Contractor shall submit a quality control plan within 15 days of contract award.
2.0. OCCUPATIONAL HEALTH NURSING.
2.1 NURSES’ STATIONS. The Contractor shall staff and operate two nurses’ stations with Occupational Health Nurses (OHNs) at DSCC, Monday through Friday. No work shall be performed on the ten (10) Federal holidays (New Year’s Day, Martin Luther King Day, Presidents’ Day, Memorial Day, Independence Day, Labor Day, Columbus Day, Veterans’ Day, Thanksgiving Day, and Christmas Day) unless authorized by the Contracting Officer. The Nurse’s Station in Building 20 will be operated by an OHN from 0630 to 1500. The Nurse’s Station in Building 20 will close for one (1) hour during 1100 to 1200 to accommodate a 30 minute lunch period, and 30 minutes of office time. The Nurse’s Station in Building 21 will be operated by an OHN from 0830 to 1700. The Nurse’s Station in Building 21 will close for one (1) hour during 1200 to 1300 to accommodate a 30 minute lunch period, and 30 minutes of office time. OHNs will be under the direct supervision of an OHP, who may supervise the Nurse’s Stations from a medical facility located off-site. Deliverable: Biweekly time and attendance for each nurse station.
2.1.1 Historical Volume. The Nurse’s Stations receive approximately 9,200 visits per year for services including: over-the-counter medications, blood pressure checks, health counseling, sprains and strains, abrasions, epigastric distress complaints, conjunctivitis and foreign bodies in eyes, headaches, application of ice packs/heat packs, and allergy shots, etc.
2.1.2 Square Footage. The square footage of the nurse station in Bldg 20 is 420 sq ft with an additional 230 sq ft as a waiting area. The square footage of the nurse station in Bldg 21 is 700 sq ft with an additional 240 sq ft as a waiting area.
2.2 TREATMENT. The OHNs will provide first aid for minor injuries and illnesses during hours of operation, and appropriate palliative care in order to enable an individual to return to the workplace. The Nurses’ Stations will dispense over-the-counter medications on a per-incident basis. The intent of providing medication is to allow the individual to complete one work shift and seek treatment later from the individual’s personal physician. The OHP will determine which medications are appropriate for the Nurses’ stations. The OHNs will provide any nursing care ordered by an individual’s private doctor when:
a. The order requires the nursing care to be done during station operating hours either for medical reasons or because the care requires the patient to leave the workplace during operating hours to obtain the care elsewhere.
b. The nursing care does not require a physician to be present
c. The nursing care does not exceed 30 minutes per day
d. The individual provides all medications and medical supplies
e. The order contains sufficient written instructions (maintained in the medical record of the individual) from the private medical provider to the OHN.
2.3 ALLERGY SHOTS. Allergy shots will be provided at both nurse stations, only during times when the OHP is present.
2.4 LOGS OF SERVICE. The OHNs will maintain a daily log of medical services provided under this contract for each Nurse Station. The log will include, at a minimum, the time and date, services provided (blood pressure, dispense medication, health counseling, etc) and whether the reason for each visit is occupational.
These logs will not replace adequate documentation in the individual’s medical record. Deliverable: Copies of monthly log for each Nurse Station.
2.5 EMERGENCIES. The DLA Installation Support Fire Department handles emergencies. The OHNs and OHP are not required to respond to an emergency outside the Nurses’ Stations.
2.6 BIOHAZARDOUS WASTE. The Contractor will equip the Nurses’ Stations with biohazardous waste containers suitable for both general contaminated trash and “sharps”. The waste containers will be used for the disposal of all biohazardous waste produced by the Nurses’ Stations AND for biohazardous waste produced on Center (currently estimated to average less than 1 pound/week). The Contractor will provide for the regular removal of biohazardous waste, no less than 1 week after filling biohazardous waste container or once per quarter, whichever is sooner. Deliverable: Waste Manifest and month infectious waste generation log.
2.7 SICK LEAVE. The OHN may recommend to an individual’s supervisor that an individual needs sick leave.
3.0 OCCUPATIONAL HEALTH PHYSICIAN SERVICES
3.1 DOCTOR’S HOURS. The OHP will spend at least 12 hours a week on Center, and no less than 2 days per week. The OHP must distribute time between both nurses’ stations. Time distribution does not have to be equal. The Contractor will provide a proposed schedule for the OHP to the COTR within 10 days of award of contract, and 10 days prior to any changes. The Doctor’s responsibilities during the hours on Center will include, but are not limited to: conducting medical examinations, reviewing charts to include assessments of medical examinations, reviewing handicap parking requests (Attachment 15), reviewing accommodations requests (requests of specialized ergonomic equipment or other devises not normally provided without supporting medical documentation – Attachment 16), and determining vaccines required for travel (less than 30 days) outside the United States. Note: Additional Manpower. Additional physician hours will be required during the months of January, February, and March to support heavy medical surveillance exam (see paragraph 3.2.5) schedule. Additional physician hours will be billed when OHP hours exceed 16 hours in a week.
Deliverables: OHP schedule. OHP biweekly time and attendance.
3.2 MEDICAL EXAMINATIONS. The OHP will conduct scheduled examinations for pre-employment, medical surveillance, fitness for duty, termination examinations, and overseas deployments at the Bldg 20 Nurses’ Station. The Contractor will promptly contact each point of contact and schedule an appointment for the appropriate physical examination. Individual medical services which cannot be conducted at the Nurses’ Station (such as x-rays) shall be completed at the Clinic. Medical services not previously authorized, but determined appropriate, must be approved by the COTR prior to performing.
All results and necessary restrictions will be reviewed with the affected individual. Deliverable: The Contractor will provide written documentation of services provided to the COTR within five (5) working days of the examination.
3.2.1 Exams performed by month. The following is a list of projected examinations to be performed.
January – 40 to 50 exams
February – 32 to 42 exams
March – 32 to 42 exams
April –December – 15 to 30 exams each month
3.2.2 General Examination Requirements. As part of every medical examination the Contractor will conduct as a minimum:
A review of the individual’s work history.
A review of the relationship, if any, between the individual’s health and his/her work environment.
A review of the relationship, if any between the individual’s physical condition and his or her job demands.
A vision screening, performed on each eye individually, and both eyes together, (while the individual is wearing safety glasses, if applicable) including near and far visual acuity, near and far phoria, color blindness, and depth perception.
3.2.3 Audiograms. An audiogram will include frequencies of 500, 1000, 2000, 3000, 4000, 6000, and 8000 Hz. A test for each frequency shall be conducted separately for each ear. All audiograms will be reviewed and signed by the OHP. Age corrections shall not be applied to audiograms when evaluating potential Standard Threshold Shifts (STS). Up to two (2) additional audiograms will be performed prior to confirming that a STS has occurred. If the OHP determines that an individual has experienced a STS, the OHP will notify the individual in writing, counsel the individual on the results, and notify the COTR. The OHP will indicate whether or not the STS appears to be work-related. The Contractor will maintain a list of individuals with STS.
3.2.4 PRE-EMPLOYMENT EXAMINATIONS. The COTR will provide the Contractor with the name of the prospective individual, contact information, job description and services authorized. Pre-employment exams are to be completed within 30 calendar days after receipt of the request. The following services are typically associated with pre-employment, fitness for duty, and termination examinations:
PRE-EMPLOYMENT EXAMINATIONS
| CLIN(s) |
| Supplies/Services |
| 0005 |
| Physical examination (except injuries) |
| 0009 |
| Pulmonary Function (FVC, FEV1, FEV1/FVC) |
| 0011 |
| Chest X-ray (2 views, “B” reader) |
| 0017 |
| Complete Blood Count (including Platelet and Differential) |
| 0018 |
| Blood Chemistry (including but not limited to: glucose, BUN, SGOT, creatine, alkaline phosphates, total bilirubin, GGT, cholesterol) |
| 0019 |
| Cholinesterase (RBC and serum) |
| 0023 |
| Urinalysis w/microscopic examination |
| 0028 |
| Beta 2 Microglobulin |
3.2.5 MEDICAL SURVEILLANCE PROCEDURES. The Contractor will conduct medical surveillance physicals on designated individuals to detect incipient health effects that may be due to exposures on the job. The COTR will provide the Contractor with a list of individuals monthly that require a medical surveillance examination. The list will include the individuals’ names; contact information, potential hazards associated with each individual’s job, services authorized, and any special requirements which may apply (such as those for Police Officers – Attachment 17) (Radiation Monitoring Program – Attachment 18 paragraphs 6-7, on pages 6 and 7). Medical surveillance exams are to be completed within 45 calendar days after receipt of the list. The Contractor will update or correct personal information provided on the medical surveillance request form as necessary.
3.2.5.1 The following services are typically associated with medical surveillance examinations:
MEDICAL SUREVELIANCE PROCEDURES
| CLIN(s) |
| Supplies/Services |
| 0005 |
| Physical examination (except injuries) |
| 0009 |
| Pulmonary Function (FVC, FEV1, FEV1/FVC) |
| 0011 |
| Chest X-ray (2 views, “B” reader) |
| 0017 |
| Complete Blood Count (including Platelet and Differential) |
This is the start of the file's text. The full file is on GovTribe.